| 摘要 |
The present invention relates to compounds, as represented by the general formula (I), that can be used as tyrosine kinase inhibitors, pharmaceutically acceptable salts thereof, esters thereof, solvates thereof, and stereoisomers thereof, R1, R2, R3, Z1, Z2, A, B, C, X and Y being as defined in the specification. The present invention also relates to a method for preparing these compounds, pharmaceutical compositions and a kit containing these compounds, and uses of these compounds. For example, the compounds of the present invention can be used as tyrosine kinase inhibitors, or used to reduce or inhibit the activity of EGFR or mutants thereof (for example, EGFR mutants containing T790M mutation) in cells, or used to treat and/or prevent diseases (for example, cancer) related to overactivity of EGFR, especially drug-resistant diseases (for example, cancer) caused by mutation of EGFR (for example, T790M mutation of EGFR). |
